GLP-1 Medications 2026: A Las Vegas & Henderson Physician's Guide
By Charles Kamen, MD, board-certified neurologist
The 2026 GLP-1 landscape centers on three medications that differ by how many gut-hormone pathways they activate: semaglutide (a single GLP-1 receptor agonist), tirzepatide (a dual GLP-1/GIP agonist), and retatrutide (a triple GLP-1/GIP/glucagon agonist). Semaglutide and tirzepatide are FDA-approved for chronic weight management; retatrutide is still under regulatory review.
Dr. Charles Kamen, MD, a board-certified neurologist at LiveNow Longevity in Las Vegas, chooses between these medications only after a complete evaluation — never by default dose or marketing. This guide explains the 2026 options and how that decision is made. Individual results vary with any approach.
What GLP-1 medications are available in 2026?
Three medications dominate weight-management care in 2026, separated by how many hormone receptors each one targets. Semaglutide activates the GLP-1 receptor alone. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist. Semaglutide and tirzepatide are FDA-approved for chronic weight management; retatrutide remains under regulatory review — our retatrutide in Las Vegas guide covers exactly where it stands.
- Semaglutide — a single GLP-1 receptor agonist, FDA-approved for chronic weight management.[2]
- Tirzepatide — a dual GLP-1/GIP agonist, FDA-approved for chronic weight management.[1]
- Retatrutide — a triple GLP-1/GIP/glucagon agonist, under regulatory review and potentially available for physician-supervised use through compounding pharmacies under federal and state regulations.[3]
The 2026 Landscape at a Glance
The practical differences between these three come down to how many receptors each engages, whether it is actually approved, and what evidence exists behind it. That last column is where the gap between them is widest.
| Medication | Receptors | Status for weight management | Evidence stage |
|---|---|---|---|
| Semaglutide | GLP-1 | FDA-approved | Phase 3 completed — STEP 1 reported −14.9% mean weight change at 68 weeks[2] |
| Tirzepatide | GLP-1 + GIP | FDA-approved | Phase 3 completed — SURMOUNT-1 reported −15.0% to −20.9% across doses at 72 weeks[1] |
| Retatrutide | GLP-1 + GIP + glucagon | Not FDA-approved. Under regulatory review | Phase 2 only at the time of the trial published in 2023[3] |
How do GLP-1, GIP, and glucagon work for weight loss?
Each added receptor gives the medication another lever on appetite and metabolism. GLP-1 slows gastric emptying and signals fullness through appetite centers in the brain. GIP, a second incretin hormone, sharpens the insulin response and influences how fat tissue handles nutrients. Glucagon, retatrutide's third target, raises energy expenditure and helps mobilize stored fat.
Appetite is regulated in the brain, not the stomach — GLP-1 receptors sit in the hypothalamic and brainstem circuits that set hunger and satiety. As a board-certified neurologist, Dr. Kamen pays close attention to how these centrally acting medications affect appetite, energy, and mood, not only the number on the scale.
How does a physician-led Las Vegas clinic choose between them?
There is no universal first-line answer. The right medication depends on your BMI, prior weight-loss attempts, comorbidities, medical history, current medications, lab work, and goals. At our Las Vegas peptide clinic, that choice is made only after a complete $88 evaluation with Dr. Charles Kamen, MD — never by default dose or marketing.
We do not auto-prescribe the highest-dose version of any medication, and we do not promise specific weight-loss results. Protocols are designed individually and supervised over time. If GLP-1 therapy is not appropriate for you, you get that answer directly.
What to expect from a 2026 GLP-1 evaluation
The evaluation is the most important part of the process. It includes a clinical consultation with Dr. Kamen, a review of your medical history and current medications, a comprehensive lab panel, and a goal-based discussion. After labs return, he reviews the results with you and designs a protocol only if it is indicated.
That protocol may include peptide therapy, NAD+, prescription weight-loss medications, hormone optimization, IV therapy, or targeted lifestyle changes — but only after evaluation and only when medically appropriate. The goal is durable metabolic improvement, not the fastest possible drop on the scale.
Protecting muscle while losing fat
Rapid weight loss reduces both fat and muscle, so a well-run GLP-1 protocol works to protect lean mass while it lowers fat. Supervised care pairs the medication with adequate protein, resistance training, and monitoring, so more of the weight lost is fat — including the visceral fat around the organs that most affects long-term metabolic health.
Retatrutide's glucagon component is of particular interest here, because glucagon receptor activation helps mobilize fat stored in the liver and abdomen. Losing visceral and hepatic fat — not just scale weight — is what improves metabolic health, which is why body composition and labs, not the scale alone, guide the plan.
Key Takeaways
- Semaglutide is a single GLP-1 receptor agonist, FDA-approved for chronic weight management.
- Tirzepatide is a dual GLP-1/GIP agonist, FDA-approved for chronic weight management.
- Retatrutide is a triple GLP-1/GIP/glucagon agonist and remains under regulatory review in 2026.
- There is no universal first-line GLP-1 — the right choice depends on BMI, comorbidities, medications, labs, and goals, not marketing.
- A supervised protocol protects muscle with protein and resistance training while targeting visceral and hepatic fat, not just scale weight.
- All three medications require physician supervision, lab monitoring, and lifestyle support; the initial evaluation is $88.
Common Questions
Which GLP-1 medication is right for me in 2026?
There is no universal first-line answer. The right choice depends on your BMI, prior attempts, comorbidities, current medications, labs, and goals — and on your response over time. A physician-led evaluation sorts this out. See our <a href="/peptide-clinic-las-vegas">Las Vegas peptide clinic</a> page to schedule.
How much do GLP-1 medications cost in Las Vegas?
The initial medical evaluation is $88 and includes a consultation, lab work, and a goal-based discussion. Ongoing protocol costs depend on the medication, dose, and your individualized plan, so they are set only after evaluation. See our <a href="/blog/peptide-therapy-cost-las-vegas">peptide therapy cost in Las Vegas guide</a>.
Do you serve Henderson patients for GLP-1 therapy?
Yes. Most of our weight-management patients come from Henderson, Green Valley, Anthem, and Seven Hills, and care is supervised the same way wherever you live in the valley. See our <a href="/peptide-clinic-henderson">Henderson peptide clinic page</a> for details and scheduling.
Will I lose muscle on a GLP-1 medication?
Any rapid weight loss can reduce muscle along with fat, so a supervised protocol works to prevent it. Adequate protein intake, resistance training, and monitoring help preserve lean mass, so more of the weight you lose is fat. This is a core reason GLP-1 therapy should be physician-supervised.
Do GLP-1 medications reduce visceral or belly fat?
They reduce overall body fat, including the visceral fat packed around the organs that most affects metabolic health. The glucagon component of retatrutide is of particular interest for mobilizing liver and abdominal fat. Because scale weight alone can mislead, body composition and labs are tracked to confirm the fat you are losing.
Is retatrutide available in Las Vegas in 2026?
Retatrutide is a triple GLP-1/GIP/glucagon agonist that remains under regulatory review. It may be available for physician-supervised use through compounding pharmacies under federal and state regulations. Whether it fits your situation is decided during evaluation, not by default — semaglutide or tirzepatide is often the appropriate starting point. See our <a href="/blog/retatrutide-las-vegas">retatrutide in Las Vegas guide</a> for the full picture.
The 2026 GLP-1 landscape gives Las Vegas patients more options than ever — and the right next step is a complete medical evaluation by a physician who designs and supervises protocols individually. Schedule at our Las Vegas peptide clinic or our Henderson peptide clinic.
References
- Jastreboff AM, et al. NEJM. 2022;387(3):205-216.
- Wilding JPH, et al. NEJM. 2021;384(11):989-1002.
- Jastreboff AM, et al. NEJM. 2023;389(6):514-525.
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.